Clinical Trial Update: The Efficacy and Safety of Tocilizumab for Severe RP-ILD Secondary to Systemic Diseases [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the efficacy and safety of tocilizumab for rapid progressive interstitial lung diseases associated with systemic diseases.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rapid Progressive Interstitial Lung Disease

Drugs mentioned

• Tocilizumab (tocilizumab)

Snippet

Sponsor: Peking Union Medical College Hospital | Conditions: Rapid Progressive Interstitial Lung Diseases | Phase 2 | Status: UNKNOWN